ReviewThe Lancet. Haematology2020
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.
Open access · bronzeAbstract readReview
In one paragraph
Review in The Lancet. Haematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Guideline
- Assessing the impact of COVID-19 on acute leukemia patients: a comparative analysis of hematological and biochemical parameters.BMC infectious diseases · 2024Article
- Do prior neurological comorbidities predict COVID-19 severity and death? A 25-month cross-sectional multicenter study on 7370 patients.Acta neurologica Belgica · 2023Article
- COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA).Haematologica · 2023Article
- Cerebrovascular accident in a child with precursor B-cell acute lymphoblastic leukemia and coronavirus disease 2019: a case report.Journal of medical case reports · 2022Article
- Article
- Assessment of Anxiety, Depression, Work-Related Stress, and Burnout in Health Care Workers (HCWs) Affected by COVID-19: Results of a Case-Control Study in Italy.Journal of clinical medicine · 2022Article
- Review
- Review
- How the COVID-19 Pandemic Reshaped the Management of Leukemia and Affected Patient Outcomes.Current treatment options in oncology · 2022Review
- Mortality by COVID-19 in adults with acute myeloid leukemia: a survey with hematologists in Brazil.Annals of hematology · 2022Article
- Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report.Mediterranean journal of hematology and infectious diseases · 2022Article
- Spontaneous Complete Remission of Acute Myeloid Leukemia in the Absence of Disease-Modifying Therapy following Severe Pulmonary Involvement by Coronavirus Infectious Disease-19.Case reports in hematology · 2022Article
- Article
- Treatment Approaches for Managing Patients with Hematological Malignancies in the Time of COVID-19 Pandemic.Turkish journal of medical sciences · 2021Review
- Oral hypomethylating agents: beyond convenience in MDS.Hematology. American Society of Hematology. Education Program · 2021Article
- Article
- Changes in Dietary Patterns and Clinical Health Outcomes in Different Countries during the SARS-CoV-2 Pandemic.Nutrients · 2021Review
- Myeloproliferative neoplasm questionnaire: assessing patient disease knowledge in the modern digital information era.Leukemia & lymphoma · 2021Article
- The Care of the Leukemic Patients in Times of SARS-CoV-2.Current oncology reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
52 authors at 20 institutions in 8 countries.
Amer M ZeidanSection of Hematology, Yale School of Medicine, Yale University, New Haven, CT, USA; Yale Comprehensive Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA. Electronic address: amer.zeidan@yale.edu.
Prajwal C BodduSection of Hematology, Yale School of Medicine, Yale University, New Haven, CT, USA; Yale Comprehensive Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA.
Mrinal M PatnaikDepartment of Hematology, Mayo Clinic, Rochester, MN, USA.
Jan Philipp BewersdorfSection of Hematology, Yale School of Medicine, Yale University, New Haven, CT, USA; Yale Comprehensive Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA.
Maximilian StahlDepartment of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Raajit K RampalDepartment of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rory ShallisSection of Hematology, Yale School of Medicine, Yale University, New Haven, CT, USA; Yale Comprehensive Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA.
David P SteensmaDepartment of Hematology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, USA.
Michael R SavonaDepartment of Hematology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Mikkael A SekeresLeukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.
Gail J RobozDepartment of Hematology and Oncology, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA.
Daniel J DeAngeloDepartment of Hematology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, USA.
Andre C SchuhDivision of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.
Eric PadronDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
Joshua F ZeidnerDivision of Hematology and Oncology, Lineberger Comprehensive Care Center, University of North Carolina, Chapel Hill, NC, USA.
Roland B WalterDivision of Hematology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Francesco OnidaDepartment of Hematology, IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Amir FathiDepartment of Hematology, Centre for Leukemia, Massachusetts General Hospital, Boston, MA, USA.
Amy DeZernDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Gabriela HobbsDepartment of Hematology, Centre for Leukemia, Massachusetts General Hospital, Boston, MA, USA.
Eytan M SteinDepartment of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Paresh VyasMRC Molecular Haematology Unit, BRC Oxford Department of Haematology, University of Oxford, Oxford, UK.
Andrew H WeiDepartment of Clinical Haematology, Alfred Hospital, Melbourne, VIC, Australia.
David T BowenDepartment of Haematology, Leeds Teaching Hospitals National Health Service Trust, Leeds, UK.
Pau MontesinosDepartment of Haematology, Hospital Universitario y Politecnico La Fe, Valencia, Spain; CIBERONC, Instituto Carlos III, University of Valencia, Madrid, Spain.
Elizabeth A GriffithsLeukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Amit K VermaDepartment of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA.
Alla KeyznerDivision of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Michal Bar-NatanDivision of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Shyamala C NavadaDivision of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Marina KremyanskayaDivision of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Aaron D GoldbergDepartment of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Aref Al-KaliDepartment of Hematology, Mayo Clinic, Rochester, MN, USA.
Mark L HeaneyDepartment of Hematology, Herbert Irving Comprehensive Care Centre, Columbia University, New York, NY, USA.
Aziz NazhaDepartment of Hematology, Cleveland Clinic-Taussig Cancer Institute, Cleveland, OH, USA.
Huda SalmanDepartment of Internal Medicine, Stony Brook University Cancer Center, Stony Brook, NY, USA.
Selina LugerDepartment of Medicine, Hematology and Oncology Division, University of Pennsylvania, Philadelphia, PA, USA.
Keith W PratzDepartment of Medicine, Hematology and Oncology Division, University of Pennsylvania, Philadelphia, PA, USA.
Heiko KonigIndiana University Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, Indiana University, Indianapolis, IN, USA.
Rami KomrokjiDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.
Michael DeiningerHuntsman Cancer Institute, Department of Medicine, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA.
Blanca Xicoy CiriciClinical Haematology Department, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
Vijaya Raj BhattFred and Pamela Buffett Cancer Center, Department of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, USA.
Lewis R SilvermanDivision of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Harry P ErbaDuke Cancer Institute, Department of Medicine, Division of Hematologic Malignancies and Cellular Therapies, Durham, NC, USA.
Pierre FenauxDepartment of Hematology, Hôpital St Louis, Assistance Publique-Hôpitaux de Paris, Paris, France; Department of Haematology, Paris University, Paris, France.
Uwe PlatzbeckerDepartment of Medicine, Division of Translational Hematology, Leipzig University Hospital, Leipzig, Germany.
Valeria SantiniDepartment of Medicine, University of Florence Medical School, Florence, Italy.
Eunice S WangLeukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Martin S TallmanDepartment of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Richard M StoneDepartment of Hematology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, USA.
John MascarenhasDivision of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Icahn School of Medicine at Mount Sinai · USMemorial Sloan Kettering Cancer Center · USDana-Farber Cancer Institute · USYale Cancer Center · USCleveland Clinic · USMassachusetts General Hospital · USMayo Clinic in Arizona · USMoffitt Cancer Center · USRoswell Park Comprehensive Cancer Center · USUniversity of Pennsylvania · USAssistance Publique – Hôpitaux de Paris · FRCentro de Investigación Biomédica en Red de Cáncer · ESColumbia University · USCornell University · USDuke Medical Center · USFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITFred Hutch Cancer Center · USIndiana University Melvin and Bren Simon Comprehensive Cancer CenterJohns Hopkins University · USLeipzig University · DE
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MYale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI Eric P. Winer · 1985 to 2026
$85.0MDana Farber/Harvard Cancer Consortium Career Development Program in Clinical OncologyK12CA087723 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Tsai Ting · 2002 to 2026
$17.9MMedical Research Council G1000729Medical Research Council MC_U137961146Medical Research Council MC_UU_00016/11Medical Research Council MC_UU_12009/11Medical Research Council MR/L008963/1NCATS NIH HHS UL1 TR001863NCI NIH HHS K12 CA087723NCI NIH HHS P30 CA016086NCI NIH HHS P30 CA016359
Abstract
The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts.
Indexed as
AdultBetacoronavirusCoronavirus InfectionsCOVID-19Disease ManagementExpert TestimonyHumansInfection ControlLeukemiaMyeloproliferative DisordersPandemicsPneumonia, ViralPractice Guidelines as TopicResource AllocationSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.